1.mRNA新锐虹信生物完成A轮融资 IT桔子出品 融资交易 15 December 星期一 每周精选 不可错过 WEEKLY NEWS 虹信生物完成A轮融资，吸引了IDG资本、经纬创投、腾讯投资等顶级风投重注。该公司拥有自主知识 产权的核酸递送系统，这是mRNA技术的核心壁垒。作为下一代RNA疗法新锐，其获得知名机构投资， 显示资本市场对中国原创RNA平台技术的高度信心。 虹信生物位于广东深圳，成立于2021年，是一家专注于核酸药物递送和RNA药物研发的生物科技公 司。公司已建立自主的可离子化氨基脂质库，致力于在肿瘤、遗传病等领域开发创新mRNA药物。 2.积塔半导体完成新一轮融资，中信、中金、中国电子联合入局 积塔半导体完成D轮融资，投资方包括中信金石、中金资本及中国电子-中电投资等"国家队"产业资本。 此轮融资凸显了积塔半导体在国家半导体产业链中的战略支点地位。在高端逻辑制程受限的背景下，其 专注汽车电子、工业控制等领域的特色工艺，是中国半导体实现差异化竞争和自主可控的关键路径。 积塔半导体位于上海浦东新区，成立于2017年，专注于半导体集成电路芯片特色工艺的研发与制造，为 汽车电子、工业控制和高端消费 ...

央视网消息："十五五"规划建议明确提出，要推动科技创新和产业创新深度融合，加快重大科技成果高效转化应用，营造具有全球竞争力 的开放创新生态。然而从实验室到生产线，转化之路往往面临资金、中试、人才等多重堵点。为此，深圳首创了"科创青藤成果转化服务体 系"，这是一个覆盖全市的有组织、系统化的成果转化生态。如何"顺藤摸瓜"，推动创新成果转化落地？下面就跟随记者镜头，一起去探访这 个发展中的创新机制，我们先到创新孵化的种子库去看一看。 操作灵活，可自主进行运动控制的绳驱灵巧手；一句话、一张图就能生成3D作品的人工智能大模型；可以自主规划，提供保洁服务的轮 臂机器人……作为粤港澳大湾区首个专注于大模型领域的垂直孵化器，这个由深圳南山区主导的"模力营"成立一年多来，已吸引了140多家人 工智能与机器人企业在这里孵化集聚。这些团队大多处在初创期，有的只有三四个人，有的已经发展到数十人，创业者大多是"95后"，还有一 些"00后"。虽然他们创意满满，但也普遍面临资金、场地、资源对接等现实挑战。 模力营培育的是人工智能领域具有潜力的创新"种子"，他们大多来自重点科创比赛、高校以及一些专业技术经理人的推荐。进入"青藤"的 种子库 ...

Core Viewpoint - The mRNA drug developer DeepTrust Bio plans to go public in Hong Kong, potentially raising around $200 million, with discussions on IPO scale and timing still in preliminary stages [1] Company Overview - DeepTrust Bio was established in 2019 and is one of the few companies globally that possesses core technology for LNP (lipid nanoparticle) design [1] - The company has developed an mRNA-LNP technology platform with proprietary intellectual property, including a library of over 5,000 ionizable lipid resources for screening LNP carriers suitable for various therapeutic scenarios [1] - DeepTrust Bio has multiple internal research pipelines in the fields of infectious disease vaccines, rare diseases, and tumor immunotherapy [1] Investment Background - According to Qichacha data, DeepTrust Bio has undergone several rounds of financing, with investors including Huaxing Capital, Dinghui Investment, CPE Yuanfeng, Qianhai Fangyuan Capital, E Fund, Blue Ocean Capital, Zhongke Chuangxing, Qianhai Mother Fund, Dongpingheng Capital, Junlian Capital, Zhifei Biological, and Lanting Capital [1]

Group 1 - DeepSeek and Yushu Technology were recognized as "smart companies" by MIT Technology Review, highlighting their innovative technology and sustainable business models [3] - The founder of Xibei, Jia Guolong, acknowledged his mistakes in handling a recent controversy and expressed intentions to adopt a more transparent approach, learning from the practices of competitor Pang Donglai [5][6] - Xibei's flagship store in Beijing experienced a significant drop in customer traffic, with a reported decrease of over 70% following the frozen vegetable controversy [12] Group 2 - The ongoing dispute between Jia Guolong and Luo Yonghao regarding the pre-made dishes incident has led to calls for a public live debate to clarify the situation [8][11] - Xibei has temporarily suspended kitchen tours in its restaurants to ensure normal operations and address customer concerns about privacy during filming [12] - The marketing consulting firm Huayi Huayi confirmed that it received over 60 million yuan in consulting fees from Xibei over the past decade, which has sparked discussions about the value of such consulting services [11] Group 3 - Penske Media Corporation (PMC) has filed a lawsuit against Google, alleging that the tech giant illegally used its news content to generate AI summaries, resulting in decreased website traffic [14] - Tesla's German factory plans to increase production due to strong sales data, despite a reported 39% drop in new car registrations in Germany last month [21] - Yao Tang Biotechnology completed a Series B financing round exceeding 300 million yuan, focusing on mRNA and gene editing drug development [22]

Core Insights - Nucleic acid drugs represent a third-generation drug model that enables precise disease treatment by regulating gene expression or intervening in protein synthesis, offering advantages such as targeting undruggable targets, long-lasting effects, and shorter development cycles [1][4] - The global nucleic acid drug market is projected to exceed $23 billion in 2024 and surpass $50 billion by 2030, with small nucleic acid drugs being the core segment, increasing from $2.9 billion in 2020 to $5.1 billion in 2024 [1][8] - China is rapidly advancing in the nucleic acid drug sector, supported by comprehensive policies and nearly 200 companies accelerating their development, with several products entering clinical trials and expected to launch in the next three years [1][4][10] Industry Overview - Nucleic acid drugs are therapeutic molecules based on nucleic acids (DNA or RNA) that treat diseases by directly regulating gene expression or intervening in protein synthesis [2][3] - The industry is characterized by high technical barriers and strong reliance on imported raw materials and production equipment [4] Market Dynamics - The global nucleic acid drug market is experiencing significant growth due to an aging population and rising chronic disease rates, with a compound annual growth rate (CAGR) exceeding 15% from 2023 to 2030 [6][8] - Over 900 companies are involved in nucleic acid drug development globally, with a total of 2,600 projects, of which 13.76% are for rare diseases [6][8] Competitive Landscape - The competitive landscape in China's nucleic acid drug industry is characterized by three tiers: leading companies like Wobang Pharmaceutical and Rebio Biotech, traditional pharmaceutical companies like Hengrui Medicine, and startups focusing on mRNA vaccines and new delivery technologies [10][11] - The first tier companies are gaining global market influence through technology licensing and innovative delivery systems [10][11] Future Trends - The nucleic acid drug industry in China is expected to evolve through international innovation and capital empowerment, with a focus on liver-targeted delivery and AI-assisted design [12][13] - The market is anticipated to shift from rare diseases to common diseases, with significant growth in areas such as cardiovascular and metabolic diseases, driven by advancements in production capabilities and reimbursement systems [13][14]

Core Insights - Moderna has announced the cancellation of its plan to build an mRNA drug manufacturing facility in Japan due to changes in the global and Japanese business environment [1] - The construction of Moderna's factory in China is also reported to have no progress at this time [1]